Anti-Mouse CD96 – Purified in vivo GOLD™ Functional Grade

Pricing & Details

Product No.C781
Clone
3.3
Protein
CD96
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
Tactile (T cell-activated increased late expression)
Isotype
Rat
IgG1 κ
Applications
B
,
FC
Prod No.
Size
Price
Avail.
Qty
Add to cart
C781-1.0mg
1.0 mg
$105.00
In stock
Max:
Min: 1
Step: 1
C781-5.0mg
5.0 mg
$355.00
In stock
Max:
Min: 1
Step: 1
C781-25mg
25 mg
$965.00
In stock
Max:
Min: 1
Step: 1
C781-50mg
50 mg
$1,595.00
In stock
Max:
Min: 1
Step: 1
C781-100mg
100 mg
$2,300.00
In stock
Max:
Min: 1
Step: 1
Bulk quantities available. Contact us for pricing.

Antibody Details

Product Details

Reactivity Species
Mouse
Host Species
Rat
Immunogen
Not available or unknown
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
< 1.0 EU/mg as determined by the LAL method
Purity
≥95% monomer by analytical SEC
>95% by SDS Page
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day 2-8°C
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for anti-mouse CD96 antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Other Applications Reported In Literature ?
B
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Clone 3.3 recognizes an epitope on mouse CD96.
Antigen Distribution
Mouse CD96 is mainly expressed by cells of hematopoietic origin, particularly T cells and NK cells.
Background
CD96 is a single pass type I transmembrane glycoprotein in the immunoglobulin superfamily that is heavily N-glycosylated1. Murine (m) CD96 is present at the surface of most lymphocytes, including NK, CD4+ T, CD8+ T, NKT, and γδ T cells, but not B lymphocytes, neutrophils, macrophages, or dendritic cells2. mCD96 interacts with mCD155 and nectin-1 (CD111)1. A V-like domain mediates binding of mCD96 to mCD155 via interaction between amino acids of the FG loop of one binding partner with residues in the C’C’’-loop of the other. CD96 is a member of an interaction network that includes adhesion, activation, and inhibition activities.

CD96 contains three Ig-like domains that are separated from the transmembrane domain by a long proline, serine, and threonine rich stalk that undergoes extensive O-linked glycomodification1. The stalk may play a role in orientation or presentation of the Ig-like domains. mAb 3.3 binds to the first Ig domain and competes with CD155 for binding3.

Human CD96 has a mild boosting effect on 2B4- and NKp30-mediated killing, but a direct role in the activation of NK cell-mediated cytotoxicity in vitro has not been observed 1. In contrast, mCD96 suppresses NK cells in vivo2. Blocking studies show that mCD96 competes with CD226 for CD155 binding and limits NK cell function by direct inhibition2. Additionally, blocking mCD96 in vivo with mAb 3.3 protects against metastasis in three different tumor models. The antimetastatic effect of mAb 3.3 is independent of antibody-dependent cell-mediated cytotoxicity and activating Fc receptors3,4 and is enhanced by anti-PD-1 and anti-CTLA-4 mAbs4. Suppression of metastasis by mAb 3.3 is dependent on NK cells, CD226 (DNAM-1), and IFN-γ4. Additionally, mAb 3.3 loses its antimetastatic function in CD155- and IL-12p35-deficient mice3.

Antigen Details

Protein
Ligand/Receptor
CD155, nectin 1
PubMed
NCBI Gene Bank ID
Research Area
Immunology
.
Inhibitory Molecules

References & Citations

1. Georgiev H, Ravens I, Papadogianni G, et al. Front Immunol. 9:1072. 2018.
2. Chan CJ, Martinet L, Gilfillan S, et al. Nat Immunol. 15(5):431-438. 2014.
3. Roman Aguilera A, Lutzky VP, Mittal D, et al. Oncoimmunology. 7(5):e1424677. 2018.
4. Blake SJ, Stannard K, Liu J, et al. Cancer Discov. 6(4):446-459. 2016.
Flow Cytometry

Formats Available

Products are for research use only. Not for use in diagnostic or therapeutic procedures.